Biocon gets 3 USFDA observations for Hyderabad facility

Published On 2022-07-22 07:20 GMT   |   Update On 2022-07-22 07:20 GMT
Advertisement

New Delhi: Pharma major, Biocon has recently announced that the US Food and Drug Administration (USFDA) has concluded a pre-approval inspection with 3 observations at the company's facility situated in Hyderabad.

"US FDA concluded a pre-approval inspection for Site 3, Biocon Limited, located at Hyderabad, Telangana on 20 July 2022. Three observations were cited at the end of the Inspection, which we will be addressing within the stipulated time," the company stated in a BSE filing.

"Biocon stands committed to the Quality, Safety & Efficacy of its products," the company further stated.

Read also: Biocon Biologics gets EU GMP certificate for new Bengaluru facility

Biocon Limited is an innovation-led global biopharmaceuticals company headquartered in Bangalore. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News